Initially developed to manage blood sugar levels in diabetic patients, GLP-1 agonists have gained popularity for their weight-reducing effects.

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

New research found hospital visits from Ozempic and Wegovy are rare, but can be serious. Experts explain the finding and ...